Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iCELL-OA
- Development stage
- Preclinical
- Lead developer
- iCELL Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
iCELL-OA is an adipose-derived mesenchymal stem cell (Adipose MSC) therapy developed by iCELL Biotechnology for the treatment of osteoarthritis. Adipose-derived MSCs are multipotent cells harvested from fat tissue that possess significant immunomodulatory and regenerative potential. When administered to the osteoarthritic joint, these cells are intended to reduce synovial inflammation and promote the repair of damaged articular cartilage by secreting various cytokines and growth factors (paracrine signaling) and potentially differentiating into chondrocytes. The therapy is currently in the preclinical stage of development, focusing on alleviating joint pain and slowing disease progression.
- Other names
- Adipose-derived Mesenchymal Stem CellsAdipose MSCs
Beyond the preview
Go deeper on iCELL-OA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iCELL-OA.